A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

2016126 citationsJournal Articlehybrid Open Access

Authors

Shigehiro Katayama · Saitama Medical University

Daishiro Yamada · Sendai Tateyama Tanaka School

Mikihiro Nakayama · Minamiaoyama Eye Clinic

Takashi Yamada · Bayer (Japan)

Masafumi Myoishi · Bayer (Japan)

Masaharu Kato · Bayer (Japan)

Christina Nowack ·

Abstract

When given in addition to a RAS inhibitor, finerenone reduced albuminuria without adverse effects on serum potassium levels or renal function in Japanese patients with T2DM and DN.

Topics & Keywords

Hormonal Regulation and Hypertension Ion Transport and Channel Regulation Electrolyte and hormonal disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Diabetes and its Complications

Volume 31, Issue 4, pp. 758-765

DOI: 10.1016/j.jdiacomp.2016.11.021

Field-Weighted Citation Impact: 5.07